Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary Control and Complications Study (HypoCCS)

Pituitary

Volumn 17, Issue 5, 2014, Pages 477-485

  Mo, Daojun ^a   Hardin, Dana Sue ^a   Erfurth, Eva Marie ^b   Melmed, Shlomo ^c  

^a ELI LILLY AND COMPANY   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

GH treatment; Growth hormone deficiency; HypoCCS; Morbidity; Mortality; SAGhE

Indexed keywords

RECOMBINANT GROWTH HORMONE; HUMAN GROWTH HORMONE;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CHILDHOOD DISEASE; CHILDHOOD ONSET GROWTH HORMONE DEFICIENCY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEOPLASM; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; STANDARDIZED INCIDENCE RATIO; STANDARDIZED MORTALITY RATIO; DEFICIENCY; MYOCARDIAL INFARCTION; NEOPLASMS; STROKE; YOUNG ADULT;

ADULT; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MALE; MYOCARDIAL INFARCTION; NEOPLASMS; PROSPECTIVE STUDIES; STROKE; YOUNG ADULT;

EID: 84928573292     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0529-6     Document Type: Article

References (27)

1. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, Coste J (2012) Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 97(2):416–425
2. Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G, Hokken-Koelega A (2012) Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 97(2):E213–E217
3. Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, Hoffman AR, Radovick S, Saenger P, Savage MO, Wit JM (2012) Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab 97:68–72
4. Sperling MA (2012) Long-term therapy with growth hormone: bringing sagacity to SAGhE. J Clin Endocrinol Metab 97:81–83
5. Webb SM, Strasburger CJ, Mo D, Hartman ML, Melmed S, Jung H, Blum WF, Attanasio AF, HypoCCS International Advistory Board (2009) Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab 94:392–399
6. Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, Jung H, Erfurth EM, Robison LL, HypoCCS International Advisory Board (2011) Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. Eur J Endocrinol 165(2):217–223
7. Webb SM, Mo D, Lamberts SW, Melmed S, Cavagnini F, Pecori Giraldi F, Strasburger CJ, Zimmermann AG, Woodmansee WW, International HypoCCS Advisory Board (2011) Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing’s disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab 95:630–638
8. Woodmansee WW, Zimmermann AG, Child CJ, Rong Q, Erfurth EM, Beck-Peccoz P, Blum WF, Robison LL, GeNeSIS and HypoCCS International Advisory Boards (2013) Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol 168(4):565–573
9. Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D, Zimmermann AG, Chanson P, International Hypopituitary Control Complications Study Advisory Board (2010) Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 95(1):74–81
10. Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Ho KK, Lamberts SW, Clemmons DR, HypoCCS International Advisory Board (2011) Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab 96(7):2255–2261
11. Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO (1996) Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 27:373–380
12. Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Sci Publ 82:1–406
13. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B, Xu J (2010) Deaths: final data for 2007. National vital statistics reports, vol 58, no. 19. National Center for Health Statistics, Hyattsville, pp 1–135
14. World Health Organization European Detailed Mortality Database. “Indicators.” http://apps.who.int/ghodata/. Accessed 22 Mar 2011
15. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds) (2007) SEER cancer statistics review, 1975–2004. National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2004/. Accessed 26 Nov 2010
16. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide (2002 estimates). International Agency for Research on Cancer. http://globocan.iarc.fr/. Accessed 22 Mar 2011
17. Westfall P, Hochberg Y, Rom D, Wolfinger R, Tobias R (2004) Concepts and basic methods for multiple comparisons and tests. In: Multiple comparisons and multiple tests using the SAS system, 2nd edn, 3rd printing. SAS Institute Inc, Cary, pp 13–40
18. Kleindorfer DO, Khoury J, Moomaw CJ, Alwell K, Woo D, Flaherty ML, Khatri P, Adeoye O, Ferioli S, Broderick JP, Kissela BM (2010) Stroke incidence is decreasing in whites but not in blacks: a population-based estimate of temporal trends in stroke incidence from the Greater Cincinnati/Northern Kentucky Stroke Study. Stroke 41(7):1326–1331
19. European Registers of Stroke (EROS) Investigators, Heuschmann PU, Di Carlo A, Bejot Y, Rastenyte D, Ryglewicz D, Sarti C, Torrent M, Wolfe CD (2009) Incidence of stroke in Europe at the beginning of the 21st century. Stroke 40(5):1557–1563
20. Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM (1997) Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 46(1):75–81
21. Brown P, Gajdusek DC, Gibbs CJ Jr, Asher DM (1985) Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med 313:728–731
22. Stochholm K, Juul S, Christiansen JS, Gravholt CH (2012) Mortality and socioeconomic status in adults with childhood onset GH deficiency (GHD) is highly dependent on the primary cause of GHD. Eur J Endocrinol 167(5):663–670
23. Kitamura A, Sato S, Kiyama M, Imano H, Iso H, Okada T, Tanigawa T, Yamagishi K, Nakamura M, Konishi M, Shimamoto T, Iida M, Komachi Y (2008) Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka study. J Am Coll Cardiol 52(1):71–79
24. Graham MR, Evans P, Davies B, Baker JS (2008) Arterial pulse wave velocity, inflammatory markers, pathological GH and IGF states, cardiovascular and cerebrovascular disease. Vasc Health Risk Manag 4(6):1361–1371
25. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25):3143–3421
26. de Boer H, van der Veen EA (1997) Why retest young adults with childhood-onset growth hormone deficiency? J Clin Endocrinol Metab 82(7):2032–2036
27. Radovick S, DiVall S (2007) Approach to the growth hormone-deficient child during transition to adulthood. J Clin Endocrinol Metab 92(4):1195–1200